Sibel Arinc
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Sibel Arinc has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
- Aysegul Senturk
Department of Chest Diseases, Ankara Atatürk Training and Research Hospital, Ankara, Turkey
2 shared publications - Neslihan Ozcelik
Department of Pulmonology, Faculty of Medicine, Recep Tayyip Erdogan University, 53100 Rize, Turkey
2 shared publications - Talat Kilic
Department of Pulmonology, Faculty of Medicine, Inonu University Turgut Ozal Medical Center, 44280 Malatya, Türkiye
2 shared publications - Ahmet Emin Erbaycu
Department of Pulmonology, Cigli Training and Research Hospital, Izmir Bakırçay University, 35620 Izmir, Türkiye
1 shared publication - Ali Tabaru
Soke City Hosp, Clin Pulmonol, Aydin, Turkey
1 shared publication - Arife Ulas
Department of Medical Oncology, University of Health Sciences, Bursa City Education and Research Hospital, Bursa 16250, Türkiye
1 shared publication
Latest Publications
- Open Access
- 23 May 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Impact of emphysema on biomarkers in hospitalized COPD patients with community-acquired pneumonia: a retrospective study
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder in which chronic bronchitis and emphysema coexist to varying degrees. Emphysema has distinct clinical and prognostic features. C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), and neutrophil values are used for diagnosing community-acquired pneumonia (CAP). This study investigated whether these biomarkers differ in emphysematous patients with CAP. Methods: Patients with COPD hospitalized with CAP between January 2016 and February 2023 were divided into emphysema and non-emphysema groups based on radiologic findings. Emphysema subtypes were classified, and quantitative Goddard scoring was performed. Admission demographic, clinical and laboratory data, hospital stay length and clinical outcomes (discharge, intensive care unit [ICU] transfer, in-hospital mortality) were compared between groups. CRP and PCT levels were dichotomized as low and high using predefined thresholds (CRP ≤ 200 vs. >200 mg/L; PCT < 0.10 vs. ≥0.10 µg/L). The independent effect of emphysema on low CRP and PCT levels was assessed using multivariable binary logistic regression analysis. Results: Of the 135 patients included, 71 (53%) had emphysema. Median CRP and PCT levels were significantly lower in the emphysema group than in the non-emphysema group (CRP: 116, interquartile range [IQR] 56–187 vs. 254 (IQR 213-310 mg/L); p < 0.001; PCT: 0.132 [ IQR 0.079–0.536] vs. 0.356 [IQR 0.171–1.660] µg/L; p = 0.007, respectively). Median WBC and neutrophil counts were also lower ( p = 0.036; p = 0.035, respectively). In multivariable analysis, emphysema (odds ratio [OR] 54.274; 95% Confidence Interval [CI] 14.545–202.526; p < 0.001), higher glomerular filtration rate (OR 1.021; 95% CI 1.002–1.040; p = 0.026), and prior antibiotic use (OR 4.278; 95% CI 1.199–15.264; p = 0.025) were independently associated with low CRP. For low PCT, emphysema remained the only significant predictor (OR 3.694; 95% CI 1.145–11.921; p = 0.029). Length of stay was longer in emphysema (9 vs.7 days; p = 0.010), with no differences in ICU transfer or mortality. Conclusion: In patients with emphysema, inflammatory biomarkers at CAP diagnosis were lower compared with those without emphysema. These findings suggest a potential difference in biomarker response; however, the retrospective design limits causality. Further prospective studies are needed to confirm these results and clarify their clinical relevance. Trial registration: Not applicable. This study is a retrospective observational analysis and was not registered as a clinical trial.
- 23 May 2026
- Published by Springer Nature in BMC Pulmonary Medicine
- Vol. 26 (1)
Open AccessImpact of emphysema on biomarkers in hospitalized COPD patients with community-acquired pneumonia: a retrospective study
Background: Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder in which chronic bronchitis and emphysema coexist to varying degrees. Emphysema has distinct clinical and prognostic features. C-reactive protein (CRP), procalcitonin (PCT), white blood cell count (WBC), and neutrophil values are used for diagnosing community-acquired pneumonia (CAP). This study investigated whether these biomarkers differ in emphysematous patients with CAP. Methods: Patients with COPD hospitalized with CAP between January 2016 and February 2023 were divided into emphysema and non-emphysema groups based on radiologic findings. Emphysema subtypes were classified, and quantitative Goddard scoring was performed. Admission demographic, clinical and laboratory data, hospital stay length and clinical outcomes (discharge, intensive care unit [ICU] transfer, in-hospital mortality) were compared between groups. CRP and PCT levels were dichotomized as low and high using predefined thresholds (CRP ≤ 200 vs. >200 mg/L; PCT < 0.10 vs. ≥0.10 µg/L). The independent effect of emphysema on low CRP and PCT levels was assessed using multivariable binary logistic regression analysis. Results: Of the 135 patients included, 71 (53%) had emphysema. Median CRP and PCT levels were significantly lower in the emphysema group than in the non-emphysema group (CRP: 116, interquartile range [IQR] 56–187 vs. 254 (IQR 213-310 mg/L); p < 0.001; PCT: 0.132 [ IQR 0.079–0.536] vs. 0.356 [IQR 0.171–1.660] µg/L; p = 0.007, respectively). Median WBC and neutrophil counts were also lower ( p = 0.036; p = 0.035, respectively). In multivariable analysis, emphysema (odds ratio [OR] 54.274; 95% Confidence Interval [CI] 14.545–202.526; p < 0.001), higher glomerular filtration rate (OR 1.021; 95% CI 1.002–1.040; p = 0.026), and prior antibiotic use (OR 4.278; 95% CI 1.199–15.264; p = 0.025) were independently associated with low CRP. For low PCT, emphysema remained the only significant predictor (OR 3.694; 95% CI 1.145–11.921; p = 0.029). Length of stay was longer in emphysema (9 vs.7 days; p = 0.010), with no differences in ICU transfer or mortality. Conclusion: In patients with emphysema, inflammatory biomarkers at CAP diagnosis were lower compared with those without emphysema. These findings suggest a potential difference in biomarker response; however, the retrospective design limits causality. Further prospective studies are needed to confirm these results and clarify their clinical relevance. Trial registration: Not applicable. This study is a retrospective observational analysis and was not registered as a clinical trial.
- Open Access
- 15 March 2021
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (2) , 148-152
Frequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.
- 15 March 2021
- Published by Galenos Yayinevi in Balkan Medical Journal
- Vol. 39 (2) , 148-152
Open AccessFrequency of Direct Oral Anticoagulants Usage in Acute Pulmonary Thromboembolism Treatment in Turkey (TUPEDO)
Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic range, and necessary close International Normalized Ratio (INR) monitoring. Phase 3 study results have reported that these drugs are at least as effective as warfarin and beneficial in terms of bleeding; however, studies that present up-to-date life data are necessary. Aims: To evaluate the frequency of using DOACs, which are prescribed with a limited number of indications in our country, and real-life data results. Study Design: Cross-sectional study Methods: This cross-sectional survey collected the clinical data (history, current treatment, treatment duration, etc.) of patients with pulmonary thromboembolism and who applied to the physician for follow-up between October 15, 2019, and March 15, 2020. The researchers kept the patient records sequentially. Results: Data from 836 patients with acute pulmonary thromboembolism from 25 centers were collected, and DOAC was used in 320 (38.5%) of them. The most preferred DOAC was rivaroxaban (n = 294, 91.9%). DOAC was mostly preferred because it could not provide an effective INR level with warfarin (n=133, 41.6%). Bleeding was observed in 13 (4%) patients. Conclusion: The use of direct oral anticoagulants is becoming almost as widespread as conventional therapy. Real-life data results are important for their contribution to clinical practice.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4311
General characteristics and therapeutic options in lung cancer in Turkey
ASPECT study, a prospective multicenter study conducted in Turkey with the participation of 26 centers, including all patients with lung cancer, who agreed to participate in the study, were re-evaluated in terms of demographic characteristics of patients (pts), disease characteristics, and the treatment options in lung cancer. Among 1245 cases (88.7% man) included, %83.4 had advanced stage (stage 3-4) lung cancer. Histopathologic types were squamous cell in 39.3%, adenocancer in 29.6%, SCLC in 19.0%, NSCLC in 10.2% and others. Of the pts, 45.5% had a comorbid disease, 49.3% had weight loss (at least 5% of body weight), and 31.6% had a history of cancer in family. PET-CT was used in 83.3% of the pts for diagnosis of staging. Metastasis was detected in 54.2% of pts (43.9% bone, 23.1% brain, %20.2% liver, 17.3% surrenal metastasis). Treatment options were chemotherapy in 45.9%, chemo-radiotherapy in 28.2%, and surgery in 18.4% of the pts. Chemotherapy was mostly platin based doubles including etoposide (14.9%), paclitaxel (14.0%), gemcitabine (12.3%), docetaxol (4.3%), pemetrexed (2.2%), vinorelbin (4.9%), and others. The use of targeted therapies was detected in 1.1% of the pts. Palliative radiotherapy was given in 21.1% of the pts (8.5% brain, 7.2% bone, 6.7% thorax, and others). Interventional bronchoscopy or bronchial stenting was performed in 2.0% and pleurodesis in 1.8%. Of the pts, 10.5% reported the use of herbal medicine products. Most pts with lung cancer presented in advanced stages and only 18.4% had a chance for surgery. Conventional chemotherapy and radiotherapy was the most common therapeutic options but the use of targeted therapies and interventional procedures seems to be quite low.
- 1 September 2015
- Published by European Respiratory Society (ERS)
- Vol. 46 (suppl 59) , PA4311
General characteristics and therapeutic options in lung cancer in Turkey
ASPECT study, a prospective multicenter study conducted in Turkey with the participation of 26 centers, including all patients with lung cancer, who agreed to participate in the study, were re-evaluated in terms of demographic characteristics of patients (pts), disease characteristics, and the treatment options in lung cancer. Among 1245 cases (88.7% man) included, %83.4 had advanced stage (stage 3-4) lung cancer. Histopathologic types were squamous cell in 39.3%, adenocancer in 29.6%, SCLC in 19.0%, NSCLC in 10.2% and others. Of the pts, 45.5% had a comorbid disease, 49.3% had weight loss (at least 5% of body weight), and 31.6% had a history of cancer in family. PET-CT was used in 83.3% of the pts for diagnosis of staging. Metastasis was detected in 54.2% of pts (43.9% bone, 23.1% brain, %20.2% liver, 17.3% surrenal metastasis). Treatment options were chemotherapy in 45.9%, chemo-radiotherapy in 28.2%, and surgery in 18.4% of the pts. Chemotherapy was mostly platin based doubles including etoposide (14.9%), paclitaxel (14.0%), gemcitabine (12.3%), docetaxol (4.3%), pemetrexed (2.2%), vinorelbin (4.9%), and others. The use of targeted therapies was detected in 1.1% of the pts. Palliative radiotherapy was given in 21.1% of the pts (8.5% brain, 7.2% bone, 6.7% thorax, and others). Interventional bronchoscopy or bronchial stenting was performed in 2.0% and pleurodesis in 1.8%. Of the pts, 10.5% reported the use of herbal medicine products. Most pts with lung cancer presented in advanced stages and only 18.4% had a chance for surgery. Conventional chemotherapy and radiotherapy was the most common therapeutic options but the use of targeted therapies and interventional procedures seems to be quite low.